Noninvasive biomarkers in heart transplant: 2020–2021 year in review

Qian, Xiaoxiao; Shah, Palak; Agbor‐Enoh, Sean

doi:10.1097/mot.0000000000000945

Cited by 4 publications

(4 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this technique may provide novel possibilities for LB in MCI/InfDCM. This technique showed the ability to replace EMB in post-transplant patients using analysis of donor-derived cfDNA [ 41 ]. It was also proved that the analysis of methylation patterns in cfDNA is a sensitive and specific method for cardiomyocyte damage assessment [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

A Systematic Review of miRNA and cfDNA as Potential Biomarkers for Liquid Biopsy in Myocarditis and Inflammatory Dilated Cardiomyopathy

et al. 2022

View full text Add to dashboard Cite

Myocarditis and inflammatory dilated cardiomyopathy are cardiac diseases leading to heart failure. Liquid biopsy is a concept of replacing traditional biopsy with specialized blood tests. The study aim was to summarize and assess the usefulness of microRNAs and circulating free DNA as biomarkers of myocardial inflammation. For this systematic review, we searched Scopus, Embase, Web of Science, and PubMed. All studies measuring microRNAs in serum/plasma/cardiac tissue or circulating free DNA during myocarditis and non-ischemic dilated cardiomyopathy in humans in which healthy subjects or another cardiac disease served as a comparator were included. Data were extracted and miRNAs were screened and assessed using a scale created in-house. Then, highly graded miRNAs were assessed for usability as liquid biopsy biomarkers. Of 1185 records identified, 56 were eligible and 187 miRNAs were found. We did not identify any studies measuring circulating free DNA. In total, 24 of the screened miRNAs were included in the final assessment, 3 of which were selected as the best and 3 as potential candidates. We were not able to assess the risk of bias and the final inclusion decision was made by consensus. Serum levels of three miRNAs—miR-Chr8:96, miR-155, and miR-206—are the best candidates for myocardial inflammation liquid biopsy panel. Further studies are necessary to prove their role, specificity, and sensitivity.

show abstract

Section: Discussionmentioning

confidence: 99%

A Systematic Review of miRNA and cfDNA as Potential Biomarkers for Liquid Biopsy in Myocarditis and Inflammatory Dilated Cardiomyopathy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Non-invasive surveillance for rejection has been an ongoing area of significant research and development over the last decade. 1 Especially in the last few years, there has been an increasing interest in assessing the value of donor fraction cell-free DNA (df-cfDNA) in diagnosis of acute rejection in heart transplant recipients. 1,2 Two major initiatives from NHLBI focused on the development of cfDNA assays have been undertaken, one with adult heart transplant recipients and the other in a combined cohort of pediatric and adult patients.…”

Section: Backg Rou N Dmentioning

confidence: 99%

“…1 Especially in the last few years, there has been an increasing interest in assessing the value of donor fraction cell-free DNA (df-cfDNA) in diagnosis of acute rejection in heart transplant recipients. 1,2 Two major initiatives from NHLBI focused on the development of cfDNA assays have been undertaken, one with adult heart transplant recipients and the other in a combined cohort of pediatric and adult patients. The NHLBI sponsored Genomic Research Alliance for Transplantation (GRAfT) study analyzed the differences between the donor and the recipient across SNPs to quantify donor derived cfDNA.…”

Section: Backg Rou N Dmentioning

confidence: 99%

“…Non‐invasive surveillance for rejection has been an ongoing area of significant research and development over the last decade 1 . Especially in the last few years, there has been an increasing interest in assessing the value of donor fraction cell‐free DNA (df‐cfDNA) in diagnosis of acute rejection in heart transplant recipients 1,2 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating threshold for donor fraction cell‐free DNA using clinically available assay for rejection in pediatric and adult heart transplantation

Deshpande,

Zangwill,

Richmond

et al. 2024

Pediatric Transplantation

View full text Add to dashboard Cite

BackgroundThe aims of the study were to assess the performance of a clinically available cell‐free DNA (cfDNA) assay in a large cohort of pediatric and adult heart transplant recipients and to evaluate performance at specific cut points in detection of rejection.MethodsObservational, non‐interventional, prospective study enrolled pediatric and adult heart transplant recipients from seven centers. Biopsy‐associated plasma samples were used for cfDNA measurements. Pre‐determined cut points were tested for analytic performance.ResultsA total of 487 samples from 160 subjects were used for the analysis. There were significant differences for df‐cfDNA values between rejection [0.21% (IQR 0.12–0.69)] and healthy samples [0.05% (IQR 0.01–0.14), p < .0001]. The pediatric rejection group had a median df‐cfDNA value of 0.93% (IQR 0.28–2.84) compared to 0.09% (IQR 0.04–0.23) for healthy samples, p = .005. Overall negative predictive value was 0.94 while it was 0.99 for pediatric patients. Cut points of 0.13% and 0.15% were tested for various types of rejection profiles and were appropriate to rule out rejection.ConclusionThe study suggests that pediatric patients with rejection show higher levels of circulating df‐cfDNA compared to adults and supports the specific cut points for clinical use in pediatric and adult patients with overall acceptable performance.

show abstract

Heart Transplant Rejection: From the Endomyocardial Biopsy to Gene Expression Profiling

Farcas,

Stoica,

Maier

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Heart transplant prolongs life for patients with end-stage heart failure but rejection remains a complication that reduces long-term survival. The aim is to provide a comprehensive overview of the current status in HT rejection. EMB is an invasive diagnostic tool, consisting in the sampling of a fragment of myocardial tissue from the right ventricular septum using fluoroscopic guidance. This tissue can later be subjected to histopathological, immunohistochemical or molecular analysis, providing valuable information for cardiac allograft rejection, but this procedure is not without complications. To increase the accuracy of the rejection diagnosis, EMB requires a systematic evaluation of endocardium, myocardium, interstitium and intramural vessels. There are three types of rejection: hyperacute, acute or chronic, diagnosed by the histopathological evaluation of EMB as well as by new diagnostic methods such as DSA, ddcfDNA and gene expression profiling, the last having a high negative predictive value. More than 50 years after the introduction of EMB in medical practice, it still remains the “gold standard” in monitoring rejection in HT recipients but other new, less invasive diagnostic methods reduce the number of EMBs required.

show abstract

Noninvasive biomarkers in heart transplant: 2020–2021 year in review

Cited by 4 publications

References 56 publications

A Systematic Review of miRNA and cfDNA as Potential Biomarkers for Liquid Biopsy in Myocarditis and Inflammatory Dilated Cardiomyopathy

A Systematic Review of miRNA and cfDNA as Potential Biomarkers for Liquid Biopsy in Myocarditis and Inflammatory Dilated Cardiomyopathy

Evaluating threshold for donor fraction cell‐free DNA using clinically available assay for rejection in pediatric and adult heart transplantation

Heart Transplant Rejection: From the Endomyocardial Biopsy to Gene Expression Profiling

Contact Info

Product

Resources

About